Small-Cap Recap: Fiscal 2016 Spells Sea Change For Angle; Cellnovo; Novacyt; Nanobiotix
A status update on four startups working in the molecular diagnostics and radiotherapy sectors.
You may also be interested in...
Nanobiotix gains more clinical evidence to support its nanoparticle technology in combination with radiotherapy to enhance treatment outcomes in cancer patients.
Angle is moving ahead with plans to take its Parsortix circulating tumor cell capture technology into the prostate and breast cancer diagnostic markets after securing £10.2m ($15m) in new capital through a share placement.
Cellnovo's partnership with US start-up TypeZero Technologies and its participation in an upcoming international artificial pancreas trial will allow the company to gain an early foothold in the US market before seeking FDA clearance for its diabetes management system, said to be the first and only one of its kind to have an insulin patch pump with mobile connectivity features.